F006 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies
DESCRIPTION
In the Management of Stevens-Johson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) there is a consensus concerning only the supportive care, topical and systemic treatments are still subject of controversies. In the first part will be presented the main clinical features and etiologies of SJS and TEN, the supportive care, the interest of the treatment by etanercept single dose and topical silver nitrate on large skin areas. In the second part there will be presented several systemic treatments and published data in the management of SJS/TEN. Based on literature review and on our experience, we propose different algorithms of management in SJS/TEN.
LEARNING OBJECTIVES
Describe the main clinical features, etiology and on controversies in management options of Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Discuss the results of current therapies and of innovative therapies in SJS & TEN, compare different new approaches in topical and systemic treatments of SJS/TEN.
Differentiate between different management options in SJS/TEN, present The Case For - and Against.
SCHEDULE
9:00 AM
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Still a Bunch of Management Controversies.
Marius Anton Ionescu, MD, PhD, IFAAD
9:35 AM
Current management and innovative therapies in SJS & TEN.
Jose Dario Martinez, MD, IFAAD
9:55 AM
Systemic Treatments for SJS and TEN - the Case For - and Against.
Mark D.P. Davis, MD, FAAD
10:15 AM
SJS/TEN Mimics
Lindy Peta Fox, MD, FAAD
10:15 AM
IVIG for Treatment of SJS/TEN: Current Evidence.
10:35 AM
Beyond SJS/TEN: High Stakes Mimics in Oncology Patients.
Cuong Nguyen, MD, FAAD
10:55 AM
Q&A
DIRECTOR
Marius Anton Ionescu, MD, PhD, IFAAD
Dermatology Department - University Hospital Saint Louis, Paris, France
SPEAKERS
Mark D.P. Davis, MD, FAAD
Mayo Clinic
Jose Dario Martinez, MD, IFAAD
Christus Muguerza High Specialty Hospital, University of Monterrey
Cuong Nguyen, MD, FAAD
DISCLOSURES
Mark D.P. Davis, MD, FAAD
No financial relationships exist with ineligible companies.
Marius Anton Ionescu, MD, PhD, IFAAD
AbbVie – Speaker(Honoraria); BMS – Speaker(Honoraria); Celgene Corporation – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Speaker(No Compensation Received); Laboratoire Dermatologiques d'Uriage – Advisory Board(Honoraria); Novartis – Speaker(Honoraria); UCB – Speaker(Honoraria);
Jose Dario Martinez, MD, IFAAD
No financial relationships exist with ineligible companies.
Cuong Nguyen, MD, FAAD
No financial relationships exist with ineligible companies.